NASDAQ: KYMRKymera Therapeutics Inc Stock
$113.51-0.69 (-0.6%)
Updated Jul 2, 2026
KYMR Price
$113.51
Fair Value Price
-$0.12
Market Cap
$9.34B
52 Week Low
$36.65
52 Week High
$130.05
P/E
-31.71x
P/B
6.06x
P/S
157.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.48M
Earnings
-$315.00M
Gross Margin
100%
Operating Margin
-611.26%
Profit Margin
-612%
Debt to Equity
0.08
Operating Cash Flow
-$243M
Beta
1.64
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KYMR Overview
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KYMR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KYMR
Ranked#90 of 463
Ranked#90 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important KYMR news, forecast changes, insider trades & much more!
KYMR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KYMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KYMR ($113.51) is overvalued by 92,237.92% relative to our estimate of its Fair Value price of -$0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KYMR ($113.51) is not significantly undervalued (92,237.92%) relative to our estimate of its Fair Value price of -$0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KYMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KYMR due diligence checks available for Premium users.
Valuation
KYMR fair value
Fair Value of KYMR stock based on Discounted Cash Flow (DCF)
Price
$113.51
Fair Value
-$0.12
Undervalued by
92,237.92%
KYMR ($113.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KYMR ($113.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KYMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KYMR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-31.71x
Industry
17.59x
Market
8.54x
KYMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.06x
Industry
5.6x
KYMR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KYMR's financial health
Profit margin
Revenue
$34.4M
Net Income
-$69.2M
Profit Margin
-201.5%
KYMR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KYMR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$129.4M
Debt to equity
0.08
KYMR's short-term assets ($677.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KYMR's short-term assets ($677.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KYMR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KYMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$88.8M
Investing
-$142.8M
Financing
$18.8M
KYMR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KYMR vs Biotech Stocks
Kymera Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.